U.S. biotech Amgen Inc. provided a 2021 earnings forecast below Wall Street estimates and said the company paused or halted enrollment for clinical trials of three cancer drugs.

Gilead Sciences Inc. cut the company’s 2020 revenue forecast, citing lower-than-expected demand and difficulty in predicting sales of remdesivir, the only treatment approved in the United States for patients hospitalized with Covid-19.

British drugmaker AstraZeneca topped second-quarter sales and profit estimates and backed the company’s 2020 forecasts, helped by strong sales in lockdowns of a diverse product range that includes a potential coronavirus vaccine.

Biogen reported full-year 2019 financial results, citing total revenues of $14.378 billion, an increase of 7% from the previous year.

Biotechnology giant Amgen Inc. expects up to a quarter of the company’s growth to come from Asia over the next decade, Chief Executive Officer Robert Bradway told Reuters.

AbbVie’s third-quarter 2019 global net revenue totaled nearly $8.48 billion, an increase of 3.0 percent on a reported basis (3.5 percent operationally).

Pfizer Inc. reported a higher-than-expected third-quarter 2019 profit on increased sales of the cancer drug Ibrance and a strong launch of the new heart medicine Vyndaqel.

Merck & Co. Inc. expects the company’ immunotherapy Keytruda will continue the drug’s market dominance as an initial treatment for advanced lung cancer as sales of the medicine topped $3 billion in a quarter for the first time, beating lofty Wall Street estimates.

Roche lifted the Swiss drugmaker’s 2019 sales target for the third time during the year, helped by newer medicines and as China bought more cancer drugs to treat a disease blamed for a quarter of the nation’s annual deaths.

Indivior Plc raised the company’s full-year 2019 forecasts as the embattled British drugmaker’s best-selling opioid addiction drug Suboxone fared better than expected in the face of competition from copycats.